{"abstract":"This notice, in accordance with 35 U.S.C. 209 and 37 CFR Part 404, indicates that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a start-up exclusive commercialization license to practice the inventions embodied in: (a) Technology families E-047-1994/0 and E-047-1994/1, including U.S. Patent 5,635,599 entitled \"Proteins Comprising Circularly Permuted Ligands\" [HHS Ref. E-047-1994/0-US-01], PCT Application PCT/ US95/04468 entitled \"Circularly Permutated Ligands and Circularly Permuted Chimeric Molecules\" [HHS Ref. E-047-1994/0-PCT-02], European Patent 0754192 entitled \"Proteins Comprising Circularly Permuted Ligand\" [HHS Ref. E-047-1994/0-EP-15, validated in Austria, Belgium, France, Italy, Liechtenstein, The Netherlands, Spain, Switzerland and the United Kingdom], Canadian Patent 2187283 entitled \"Proteins Comprising Circularly Permuted Ligands\" [HHS Ref. E-047-1994/0-CA-14], Australian Patent 694211 entitled \"Proteins Comprising Circularly Permuted Ligands\" [HHS Ref. E-047-1994/0-CA-14], and U.S. Patent 6,011,002 entitled \"Circularly Permutated Ligands and Circularly Permuted Chimeric Molecules\" [HHS Ref. E-047-1994/1-US-01]; (b) Technology family E-021-2010/0, including U.S. Patent Application 61/105,408 entitled \"Targeted Cargo Protein Combination Therapy\" [HHS Ref. E-021-2010/0-US-01] and U.S. Patent Application 12/ 579,281 entitled \"Targeted Cargo Protein Combination Therapy\" [HHS Ref. E-021-2010/0-US-02]; and all related continuing and foreign patents/patent applications for these technology families, to Medicenna Therapeutics, Inc. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective start-up exclusive commercialization license territory may be worldwide, and the field of use may be limited to:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/07/08/2013-16237.html","cfr_references":[],"citation":"78 FR 40757","comment_url":null,"comments_close_on":"2013-07-23","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 23, 2013 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2013-16237","effective_on":null,"end_page":40757,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/07/08/2013-16237.xml","html_url":"https://www.federalregister.gov/documents/2013/07/08/2013-16237/prospective-grant-of-start-up-exclusive-commercialization-license-the-development-of-a-circularly","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-16237?publication_date=2013-07-08","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-07-08/2013-16237/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":63,"last_updated":"2026-08-25 18:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-07-08/pdf/2013-16237.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-16237.pdf?1373028642","publication_date":"2013-07-08","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/07/08/2013-16237.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2013-07-28T06:00:14Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":40757,"subtype":null,"title":"Prospective Grant of Start-Up Exclusive Commercialization License: The Development of a Circularly Permuted IL4-Targeted Pseudomonas Exotoxin A (cpIL4-PE38KDEL) for the Treatment of Cancers and Urological Disorders","toc_doc":"Development of a Circularly Permuted IL4-Targeted Pseudomonas Exotoxin A (cpIL4PE38KDEL) for Treatment of Cancers and Urological Disorders","toc_subject":"Prospective Grants of Start-Up Exclusive Commercialization Licenses:","topics":[],"type":"Notice","volume":78}